![]() |
||||||||||
| Home | Research | Policy | Clinical Practice | For Parents | ASI | Products & Services | Resources | About Us | ||
| TRI Sections |
Medication Assisted Treatment Buprenorphine Treatment in Medicaid: study finds the evidence doesn’t support rationing buprenorphine to save State money or ensure safety. Extended Release Naltrexone (XR-NTX) for Alcohol Dependence: XR-NTX patients persisted longer with treatment than oral medication patients and had lower inpatient and ER costs. Medication Assisted Alcohol Treatment: Patients who received medication had lower healthcare utilization and total costs than those who did not. Medication Assisted Opioid Treatment: Patients with opioid dependence who received medications as part of their comprehensive treatment had lower inpatient hospital use and total costs than patients who did not receive medications.Alcoholism Medications & Healthcare Utilization: patients treated with an alcoholism medication had lower healthcare utilization than those that did not. MOTHER Study: as opposed to methadone treatment, babies born to mothers treated with buprenorphine during pregnancy showed significantly fewer withdrawal symptoms and left the hospital more quickly Buprenorphine-Naloxone Treatment for Opioid-Addicted Youth: Study by the Delaware Valley Node of the NIDA Clinical Trials Network shows significantly better outcomes for a group of young opioid-addicted patients receiving buprenorphine-naloxone (“BUP”), compared with a group receiving detoxification, with differences narrowing when the BUP group was tapered from the medication. |
|||||||||
|
||||||||||
| Quick Links | ||||||||||
|
|
||||||||||